Case Study 48: Points to Note for Lifestyle Disease Management Fees After the FY2026 Medical Fee Revision [Kirareceipt Season 4] – CareNet.com

News Highlights

Case Study 48, explaining points to note for lifestyle disease management fees in the FY2026 medical fee revision, has been published on CareNet.com. Key discussion points for medical M&A and business succession include the importance of mid-to-long-term management and succession strategies considering the revision cycle, the economies of scale through group participation (maintaining facility standards and dispersing equipment investment costs), and utilizing tax schemes including transitions to specific medical corporations and social medical corporations.

M&A Medical Editorial Department’s Perspective

The FY2026 medical fee revision is highly likely to bring specific changes to the eligibility criteria for lifestyle disease management fees. Especially with the shortening revision cycle, it is an urgent issue not only to improve single-year financial performance but also to re-evaluate mid-to-long-term management strategies, and consequently, business succession strategies. For example, a medical corporation operating multiple facilities could disperse the burden of high equipment investment costs while maintaining facility standards for lifestyle disease management fees through group formation, serving as a concrete example of business expansion and efficiency improvement through M&A. Furthermore, tax schemes that consider transitioning to specific medical corporations or social medical corporations will directly reduce the tax burden at the time of succession, promoting smooth business succession. The trends of this revision suggest that it may impact the very business structure of medical institutions, going beyond mere increases or decreases in medical fees.

Discussion Points Indicated by This News

• Responding to the shortened medical fee revision cycle and the indispensability of mid-to-long-term management and succession strategies
• Benefits of maintaining facility standards for lifestyle disease management fees and dispersing equipment investment costs through group formation
• Facilitating succession through tax schemes considering transitions to specific medical corporations and social medical corporations
• Impact of lifestyle disease management fee revisions on the business structure of medical institutions

Practical Questions Arising from This News

• What specific changes to eligibility criteria are expected with the revision of lifestyle disease management fees this time?
• From what scale of medical corporations does maintaining facility standards through group formation become effectively beneficial?
• In what situations are the tax benefits maximized when transitioning to a specific medical corporation or a social medical corporation?

If You Feel “Should I Consult Too?”

The trends of this medical fee revision, particularly concerning lifestyle disease management fees, may have an undeniable impact on your clinic’s management strategy and future business succession plan. If you feel that specialized knowledge is necessary for formulating a mid-to-long-term management plan considering the revision cycle, or for considering options such as group formation or corporate status transition, we recommend consulting with an M&A intermediary company. Simply gathering information on concrete options tailored to your clinic’s situation and their feasibility can be a preparation for the future.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics with a complete success fee basis as a certified M&A support institution by the Small and Medium Enterprise Agency. Consultations are kept strictly confidential. Free consultation here